XtalPi

AI Drug R&D Startup XtalPi Lands Massive $319M SoftBank-Led Round C To Continue Its High-Tech Drug Discovery

| < 1 minute read

XtalPi, an American-Chinese biotech firm that focuses on AI-assisted drug discovery, has raised a $319 million round C from a slate of enthusiastic investors led by SoftBank’s Vision Fund. It joins numerous others with 9-figure rounds in what is clearly a valuable and competitive space.

XtalPi works with major pharmaceutical companies like Pfizer that need to identify promising new drug-like molecules and learn as much about them as possible.

XtalPi will expand its Intelligent Digital Drug Discovery and Development (ID4) platform’s capabilities through a three-pronged approach focused on algorithms, data, and computing power to address efficiency bottlenecks throughout the critical steps of pharmaceutical research.

Across several prominent global cloud providers, XtalPi routinely builds a supercomputing cluster of over a million cores on-the-fly, in just a few hours, to enable dozens of drug discovery and design projects in parallel. In developing its digital-twin drug R&D system, XtalPi will continue to match real-world R&D data with increasingly powerful virtual simulations at scale and extend its existing success to serve a larger number of biotech partners, therapeutic areas, and drug discovery projects.

SHARE THIS POST
Posted in

About the author

Related Posts

Startup Of The Week – NutSpace

Everything we do, we do to brighten the future of our children by making them creative, innovative and better human beings. We shape the future of our children by using simple theme-based stories that are easy to understand, encourage reflection, impart knowledge and drive curiosity. We design story-based courses for children, parents and teachers. Currently, we are focusing on creating content for children (and their parents/teachers) of 0-8 years.